Medical devices, healthcare technology and the business of care
FDA RECALL RECORD · Z-1658-2026

BD Kiestra" ReadA; Catalog No.: 446948. Recall

BD Kiestra" ReadA; Catalog No.: 446948.

FDA recall Class II

Ongoing

FDA lists this Class II recall for BD Kiestra" ReadA; Catalog No.: 446948.. Review the affected identifiers, reported reason and manufacturer instructions below.

Recall at a glance

Recall number
Z-1658-2026
Recall classification
Class II
Enforcement status
Ongoing
Initiation date
Feb 6, 2026
FDA report date
Apr 8, 2026
Quantity in commerce
82 units (7 US, 65 OUS)
Distribution
See key details
FDA cause
Software Manufacturing/Software Deployment

What is being recalled?

BD Kiestra" ReadA; Catalog No.: 446948.

Affected model & UDI checker

Search the exact identifiers published for Z-1658-2026.

The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.

Affected products

Model / catalog numberProductLot scope reportedUDI / GTIN
446948BD Kiestra" ReadA; Catalog No.: 446948.Check source noticeNot specified
Not specifiedBD Kiestra" ReadA; Catalog No.: 446948.Check source notice00382904469481
FDA code information

Catalog No.: 446948; UDI-DI: 00382904469481; Serial Numbers: All;

View the original FDA recall notice

Why was this product recalled?

In certain situations, following a system reboot, one or more modules may have become unreachable via the remote connectivity interface. When this occurred, there was potential for delays in plate retrieval from the incubator while connectivity was restored. This issue was intermittent and did not affect test results, performance of the assay, or sample integrity.

These are potential consequences described in the source. The recall reason does not establish how many injuries or incidents occurred.

What actions did BD KIESTRA LAB AUTOMATION take?

On February 6, 2026 customers were contacted via phone call with a follow-up URGENT: Medical Device Correction letter were sent to customers on or about March 10, 2026. Actions to be taken: 1. Ensure the contents of this notification are read and understood. 2. Share and post this customer letter within your facility network and forward to any customers to whom you may have distributed the product to ensure awareness. 3. Complete the attached Customer Response Form and return to the BD contact noted on the form whether or not you have any of the impacted material so that BD may acknowledge your receipt of this notification per FDA requirements. 4. Report any adverse health consequences experienced with the use of this product to BD. Events may also be reported to the FDA's MedWatch Adverse Event Reporting program via: Web: MedWatch website at www.fda.gov/medwatch Phone: 1-800-FDA-1088 (1-800-332-1088)

Read the manufacturer action recorded by FDA

Recall timeline

  1. Recall initiated by firm

  2. FDA notice posted

  3. FDA classification recorded

  4. FDA enforcement report date

Related FDA submissions

No submission number with an exact verified relationship is linked in the retrieved recall notice.

FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.

Source and update history

  1. FDA enforcement data

    First stored snapshot of this source.

  2. FDA device-recall notice

    First stored snapshot of this source.

The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.

Our data sources and methodology